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Introduction
Anti-neutrophil cytoplasm autoantibody (ANCA)-asso-
ciated systemic small vessel vasculitis (SVV) (comprising 
Wegener granulomatosis and microscopic polyangiitis) is 
a group of related autoimmune disorders characterized 
by inﬂ ammatory necrosis of small blood vessels [1]. Th is 
results in dysfunction of supplied organs, and the 
principal clinical consequences are renal failure and lung 
hemorrhage. If the condition is untreated, the mortality 
at 1 year is almost 90% [2]. Despite modern treatment 
protocols, there are still mortality rates of 15% and 36% at 
1 and 5 years, respectively [3], signiﬁ cantly higher than 
other autoimmune diseases and certain malignancies. 
Th e immunosuppressive therapies used carry a heavy 
burden of adverse events; one recent study found that 
death in the ﬁ rst year is three times more likely to be due 
to an adverse event than to the vasculitis itself [4]. In 
those patients not recovering renal function, renal replace-
ment therapy carries an additional average annual cost of 
€31,000 to €40,000 ($42,240 to $54,500) per patient.
ANCAs are directed against enzymes stored in the 
azurophilic granules of neutrophils and the lysosomes of 
monocytes [5]. Several antigenic targets for ANCAs have 
been identiﬁ ed, but ANCAs directed against myelo per-
oxidase (MPO) [6] and proteinase 3 (Pr3) [7,8] are most 
common. However, vasculitic lesions contain only scant 
immune deposits (‘pauci-immune’) and do not contain 
ANCAs. Th erefore, it has been argued that these anti-
bodies are unrelated to the actual vasculitic injury and 
that they are epi-phenomena and not part of the disease 
pathogenesis. Th e last two to three decades have witnes-
sed the gradual emergence of an empirically supported 
paradigm that seeks to explain how these antibodies, 
which are so tightly associated with clinical disease, could 
exert a pathogenic eﬀ ect by direct action on neutrophils.
ANCA-SVV pathogenesis
Evidence for a pathogenic role for ANCAs comes from 
numerous in vitro observations that support the conten-
tion that ANCA-mediated eﬀ ector mechanisms contri-
bute to endothelial injury (reviewed in [9]). Th e concept 
that has emerged from these observations is that ANCAs 
and proinﬂ ammatory stimuli (most likely of infectious 
origin) synergize to cause a destructive inﬂ ammatory 
process. Th e primary event in this process is that ANCA-
mediated activation of neutrophils causes the generation 
of reactive oxygen species, release of proteases, and 
cytokine production. Full-blown ANCA-mediated neutro-
phil activation requires priming with minor proinﬂ am-
matory stimuli that induce translocation of the ANCA 
antigens to the cell surface, facilitating interaction with 
ANCAs [10]. Moreover, a recent study suggests that 
neutrophils from ANCA-SVV patients also have 
increased transcription of the ANCA antigens because of 
epigenetic modiﬁ cations associated with gene silencing 
and thus increased autoantigen availability [11]. Follow-
ing engagement of the F(ab’)2 portion of ANCAs with 
ANCA antigens on the cell surface, and Fc receptor-
mediated interactions, neutrophil activation is triggered 
[12]. Importantly, ANCAs also increase neutrophil 
adher ence to endothelial monolayers, and co-incubation 
of ANCA-activated neutrophils and endothelial cells 
results in endothelial cell lysis [13]. Th ere is a large body 
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of in vitro experimental evidence to support this para-
digm. However, to study the interplay between ANCAs, 
neutrophils, and infectious stimuli in the complex 
multicellular three-dimensional environment of renal 
and other tissues patrolled by elements of the innate and 
active immune system, animal models are required. Here, 
we will review the animal models of ANCA SVV that 
have been developed and address their advantages and 
limitations. In addition, we will discuss how these models 
have contributed to dissecting the pathogenic mecha-
nisms involved in ANCA-mediated vasculitis and how 
they have provided us with a test bed for novel therapies.
Insights from animal models into the pathogenesis 
of pauci-immune SVV in the presence of ANCAs: 
pathogenicity of anti-MPO antibodies
Development of animal models of MPO-ANCA-
mediated vasculitis has been an essential step in proving 
the direct pathogenic potential of anti-MPO antibodies 
in vivo. During the 1990s, several rodent models were 
developed in an eﬀ ort to model the eﬀ ect of anti-MPO 
antibodies [14]. Th ese involved inducing autoimmunity 
with mercuric chloride (a polyclonal B-cell stimulator) 
[15,16], planting of ANCA antigens within the kidney by 
direct infusion into the renal artery [17], or focusing the 
immune response to MPO on the kidney by adminis-
tration of subnephritogenic doses of anti-glomerular 
basement membrane (anti-GBM) antibody [18]. Th ese 
models provided evidence for the ability of anti-MPO 
antibodies to exacerbate renal injury. However, the 
development of crescentic nephritis was reliant upon the 
presence of immune complexes in the kidney, or the anti-
MPO response was part of a broad, nonspeciﬁ c, antibody 
proﬁ le. Th erefore, these approaches, though informative, 
did not accurately model the pathology of anti-MPO-
associated SVV in humans.
In 2002, Xiao and colleagues [19] demonstrated that 
systemic administration of puriﬁ ed murine anti-MPO 
IgG, obtained from murine MPO-immunized Mpo−/− 
mice, into recipient C57Bl/6 mice causes vasculitis. In 
this model, systemic injection of anti-MPO IgG resulted 
in urinary abnormalities (hematuria, leukocyturia, and 
albuminuria), early glomerular neutrophil accumu-
lation, and focal necrotising crescentic glomerulo-
nephritis in all recipient animals (Figure 1). In a subset 
of animals, vasculitic lesions were also observed in 
lungs, spleen, and ears. Shortly after this murine model 
was developed, Little and colleagues [20] developed a 
rat model of systemic anti-MPO-associated vasculitis 
(‘experimental autoimmune vasculitis’, or EAV) that was 
characterized by generation of an immune response to 
exogenously administered human MPO in adjuvant, 
followed over a period of 4 to 8 weeks by progressive 
pauci-immune cres entic glomerulonephritis and lung 
hemorrhage (Figure 2). Th e initial immune response in 
this model is to the foreign human MPO protein, but 
the anti-MPO anti bodies that develop cross-react with 
rat MPO.
Figure 1. Overview of the mouse model of anti-myeloperoxidase (anti-MPO) IgG-induced glomerulonephritis. CFA, complete Freund’s 
adjuvant.
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Th e histopathological ﬁ ndings in both of these models 
resemble, to a large extent, those in human ANCA SVV. 
For example, in agreement with the pauci-immune 
nature of the glomerular capillary lesions observed in 
human ANCA-associated glomerulonephritis, only a 
limited amount of immunoglobulins and complement 
factors is detected in the glomeruli of mice and rats with 
anti-MPO-mediated glomerulonephritis.
Both the mouse and rat models of MPO-ANCA SVV 
convincingly demonstrate the pathogenic potential of 
MPO-ANCAs but clearly also have their limitations. 
Essentially, both cannot be regarded as genuine auto-
immune models, as they rely on active immunization 
strategies that depend upon the use of adjuvants for 
disease induction. Indeed, in the murine model, the 
MPO-deﬁ cient mouse has never been exposed to any 
MPO molecule before, so the MPO molecule is eﬀ ectively 
a xeno-antigen and there is no requirement for breaking 
tolerance. As a consequence, high-aﬃ  nity antibodies 
recognizing diverse epitopes are induced.
Second, the renal phenotype of both models is mild, 
thereby limiting the ability to use them to adequately test 
novel therapies. Without the use of additional inﬂ am ma-
tory stimuli, such as lipopolysaccharide (LPS), crescent 
fraction is of the order of 5% to 10% and excretory renal 
function is preserved. Th is contrasts sharply with the 
relentless loss of kidney function observed in human 
ANCA-associated vasculitis, in which crescents often 
aﬀ ect 100% of glomeruli. Th erefore, an agent that 
successfully treats rodent vasculitis may not be eﬀ ective 
in treating the established human condition. One 
important step in making the model’s vasculitis severity 
more representative of human disease was published 
recently in abstract form by Xiao and colleagues [21], 
who made use of a diﬀ erent strain of mouse (129S6) that 
is known to be more sensitive to induction of glomerulo-
nephritis than the C57/Bl6 strain used in the original 
experiments. Using the same approach of passive transfer 
of anti-murine MPO antibodies, the authors showed that 
the 129S6 strain develops crescents in 50% to 60% of 
glomeruli, reﬂ ecting the human situation more closely. 
Th ese ﬁ ndings have not yet been replicated.
Finally, the passive transfer model developed by Xiao 
and colleagues [19] is induced by a single injection of 
anti-MPO IgG. Th erefore, the model is useful for study-
ing the induction of acute vascular injury by anti-MPO 
antibodies but is less suited for studying the chronic 
phase of the disease because of the lack of sustained 
autoantibody production. To address this issue, Schreiber 
and colleagues [22] employed a bone marrow (BM) trans-
plantation approach to develop a model in which the 
eﬀ ects of longer-term exposure to anti-MPO responses 
can be investigated. In these experiments, murine MPO-
immunized Mpo−/− mice were irradiated and transplanted 
with BM from either MPO-deﬁ cient mice or wild-type 
mice. In the recipient mice, anti-MPO antibody 
production was preserved but only engraftment of MPO+ 
BM cells resulted in crescentic glomerulonephritis, 
thereby demon strating that MPO+ BM cells are essential 
for the development of anti-MPO-mediated glomerulo-
nephritis. However, in this model, the disease is again 
relatively mild, and the contribution of radiation-induced 
tissue injury and MPO+ T cells is unclear.
Insights from animal models into ANCA-SVV 
pathogenesis: mechanisms of anti-MPO-induced 
acute vascular injury
Th e MPO-ANCA vasculitis rodent models have proven 
to be very valuable for in vivo studies of eﬀ ector 
mechanisms involved in the acute vascular inﬂ ammatory 
phase and for the evaluation of experimental therapies 
(summarized in Table 1, which is adapted from [23]). In 
the mouse model, neutrophils are the main eﬀ ector cells, 
as neutrophil depletion completely prevented vasculitis 
induction upon injection of anti-MPO IgG [24]. Further-
more, co-administration of LPS and anti-MPO IgG was 
found to severely aggravate glomerulonephritis develop-
ment [25] in a Toll-like receptor 4 (TLR4)-dependent 
manner [26]. Th ese observations support the contention 
that, following infection, proinﬂ ammatory stimuli and 
MPO-ANCAs synergize to cause full-blown vasculitis. 
To zoom in on the very early events in the interaction of 
neutrophils with the endothelium, intravital microscopy 
analysis of the mouse cremasteric microvasculature has 
been employed [27]. Th is study showed that, in the 
presence of a local inﬂ ammatory stimulus, anti-MPO IgG 
reduced neutrophil rolling while promoting adhesion and 
transendothelial migration of leuko cytes. Th ese MPO-
ANCA-mediated neutrophil-endothe lium interactions 
were found to depend upon β2 inte grins and Fcγ 
receptors.
Figure 2. Overview of the experimental autoimmune vasculitis 
rat model of anti-myeloperoxidase (anti-MPO)-associated 
systemic vasculitis. d, day; GN, glomerulonephritis; WKY, Wistar 
Kyoto.
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Th e ability of anti-MPO antibodies to increase leuko-
cyte adhesion to and transmigration through endo-
thelium is also supported by mesenteric intravital micro-
scopy experiments in the EAV rat model [20]. In addition, 
workers from Monash University in Australia have used 
renal intravital microscopy to visualize an acute increase 
in leukocyte adhesion within a more clinically relevant 
organ, the kidney, following infusion of anti-MPO anti-
bodies [28]. It is conventionally thought that leukocytes 
do not roll or adhere in glomerular capillaries, but this 
group provided evidence to support a nonclassical, α4 
integrin-mediated mechanism of neutrophil capture in 
the glomeruli. Intravital microscopy cannot yet observe 
events in glomeruli in the normal mouse, and these 
experiments have used a hydronephrotic kidney model 
that is likely to markedly alter the glomerular responses, 
thereby making it diﬃ  cult to interpret.
Insights from animal models in ANCA-SVV 
pathogenesis: an unexpected role for complement
ANCA SVV is a pauci-immune condition. One does not 
observe deposition of complement components at vascu-
litic sites, and levels of complement in the blood remain 
unperturbed unlike, for example, in systemic lupus 
erythematosus. In addition, the paradigm describing the 
pathogenesis pathway mentioned above does not include 
a role for complement. Th erefore, the ﬁ nding that mice 
depleted from circulating C3 by cobra venom factor as 
well as mice deﬁ cient in the common complement 
pathway component C5, its receptor C5aR, or the alter-
native pathway component factor B were completely 
protected against anti-MPO-induced glomerulonephritis 
was unexpected [29,30]. Moreover, in this model, 
adminis tration of a C5-inhibiting antibody markedly 
attenuated glomerulonephritis development even when 
Table 1. Summary of fi ndings obtained using MPO-ANCA vasculitis animal models
  Result Model Reference
Eff ector mechanisms   
 Neutrophil Neutrophil depletion abrogates crescentic glomerulonephritis. Mouse [24]
 T cells CD4+ eff ector T cells contribute to anti-MPO-mediated crescentic  Mouse (anti-GBM) [55]
  glomeruloneprhitis.
  Th17 cells promote anti-MPO-mediated crescentic glomerulonephritis. Mouse (anti-GBM) [56]
 Proinfl ammatory stimuli Lipopolysaccharide aggravates crescentic glomerulonephritis in a  Mouse [25]
  TLR4-dependent manner.
  Pertussis toxin/Mycobacterium tuberculosis aggravates crescentic  Rat [59]
  glomerulonephritis.
 IgG glycosylation IgG glycan hydrolysis attenuates crescentic glomeruloneprhitis. Mouse [38]
 Leukocyte-endothelial interactions Anti-MPO IgG increases leukocyte adhesion and migration in cremasteric  Rat [20]
  venules.
  Anti-MPO IgG increases leukocyte adhesion in glomerular capillaries. Mouse [27]
 Genetic susceptibility Rat and mouse strains diff er in susceptibility to anti-MPO-mediated  Rat [59]
  crescentic glomerulonephritis.
   Mouse [21]
Targets for treatment   
 Complement pathway Disruption of alternative complement pathway abrogates crescentic  Mouse [29]
  glomerulonephritis.
  Genetic ablation of C5aR attenuates crescentic glomerulonephritis. Mouse (BM) [30]
 PI3Kγ signalling Genetic ablation of PI3Kγ attenuates crescentic glomerulonephritis. Mouse (BM) [33]
Experimental therapies   
 Anti-TNFα treatment Anti-TNFα pretreatment attenuates crescentic glomerulonephritis. Rat [32]
   Mouse [25]
 Anti-C5 treatment Anti-C5 pretreatment abrogates and treatment attenuates crescentic  Mouse [31]
  glomerulonephritis.
 PI3Kγ inhibitor treatment Treatment with a PI3Kγ inhibitor attenuates crescentic glomerulonephritis. Mouse (BM) [33]
 P38 MAPK inhibitor treatment Treatment with a P38 MAPK inhibitor attenuates crescentic glomerulonephritis.  Mouse [36]
anti-GBM refers to the mouse model in which low-dose anti-glomerular basement membrane administration triggers disease in myeloperoxidase-immunized mice. 
BM refers to the bone marrow transplantation myeloperoxidase-anti-neutrophil cytoplasm autoantibody (MPO-ANCA) mouse model. C5aR, C5a receptor; MAPK, 
mitogen-activated protein kinase; PI3Kγ, phosphatidylinositol 3 kinase-gamma; Th17, T helper 17; TLR4, Toll-like receptor 4; TNFα, tumor necrosis factor-alpha. 
Adapted from [23].
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treatment was started after disease induction [31]. Th e 
exact mechanism by which anti-MPO antibodies require 
complement for their action remains to be worked out, 
but these in vivo experiments have illuminated a novel 
therapeutic target.
Insights from animal models in ANCA-SVV 
pathogenesis: testing of novel therapies
Th e rodent models of anti-MPO-mediated glomerulo-
nephritis described above have proven to be useful tools 
for testing experimental therapies. For example, thera-
peutic interventions aimed at blocking the proinﬂ am-
matory eﬀ ects of tumor necrosis factor-alpha (TNFα) 
have been evaluated in both the MPO-ANCA mouse 
model [25] and the EAV rat model [32]. In both, anti-
TNFα treatment was beneﬁ cial and ameliorated disease 
severity, although this strategy appears to be more eﬀ ec-
tive in rats. More recently, interventions have focused on 
the signalling pathways involved in ANCA-mediated 
neutrophil activation. Employing in vitro assays and the 
BM transplantation anti-MPO mouse model, Schreiber 
and colleagues [33] demonstrated a pivotal role for phos-
hatidyl inositol 3 kinase-gamma (PI3Kγ) in MPO-ANCA-
mediated neutrophil activation and glomerulonephritis 
development. In these studies, transplantation of BM 
from PI3Kγ-deﬁ cient mice into irradiated MPO-
immunized MPO−/− mice prevented glomerulonephritis. 
Similar eﬀ ects were observed in mice transplanted with 
wild-type BM upon oral treatment with a PI3Kγ-speciﬁ c 
inhibitor (AS605240), suggesting that inhibition of PI3Kγ 
might be a therapeutic option in ANCA-SVV patients.
Another signalling pathway implicated in ANCA-
mediated neutrophil activation is the P38 mitogen-
activated protein kinase (MAPK) pathway. In vitro, inhi-
bition of P38 MAPK abrogates ANCA-induced neutro-
phil activation, and there is evidence that the P38 MAPK 
pathway is activated in glomerular lesions of ANCA-SVV 
patients [34,35]. Using the anti-MPO IgG/LPS model, 
van der Veen and colleagues [36] tested the eﬀ ects of an 
orally administered P38 MAPK inhibitor on glomerulo-
nephritis development. In this study, P38 MAPK inhi-
bition was found to ameliorate disease severity, although 
the eﬀ ects were rather moderate, reducing glomerular 
crescent formation by approximately 30%. Th ese data 
suggest that, besides p38 MAPK activity, other signalling 
pathways, such as the PI3Kγ (see above) and SYK [37] 
pathways, are activated in MPO-ANCA-mediated in-
ﬂ am mation and are perhaps more important in the 
disease process.
An alternative strategy to block the pathogenic eﬀ ects 
of MPO-ANCAs was described recently by van Timmeren 
and colleagues [38], who focused on the autoantibodies 
themselves. In this study, the bacterial enzyme endo-
glycosidase S (EndoS) was used to speciﬁ cally hydrolyze 
the conserved asparagine-linked glycans on IgG heavy 
chains, abolishing Fc receptor-mediated activation of 
leukocytes and complement [39]. In vitro, EndoS treat-
ment of ANCA IgG markedly attenuated ANCA-mediated 
neutrophil activation without aﬀ ecting antigen binding 
capacity whereas injection of EndoS-pretreated anti-
MPO IgG in mice prevented glomerulonephritis develop-
ment. Moreover, systemic EndoS administration early 
after disease induction rescued mice from disease 
progres sion. Overall, these data suggest that modulation 
of IgG glycosylation by EndoS is a promising strategy to 
interfere with the early ANCA-mediated inﬂ ammatory 
processes [38].
Finally, as mentioned above, therapeutic approaches 
aimed at inhibiting complement activation may prove to 
be fruitful. However, the applicability of results from 
these and other novel therapies to human disease is 
hampered by the relatively mild phenotype in both 
models, both of which have renal disease that is much 
less severe than the kidney-threatening disease seen in 
human SVV.
Insights from animal models in ANCA-SVV 
pathogenesis: investigating anti-Pr3 antibody-
associated vasculitis
Strategies to develop Pr3-ANCA vasculitis models, in 
contrast to MPO-ANCA vasculitis models, have been 
unsuccessful so far. Using an approach similar to that of 
the murine anti-MPO antibody model, Pﬁ ster and 
colleagues [40] obtained anti-Pr3 antibodies from Pr3/
elastase double-knockout mice by immunizing with 
murine recombinant Pr3. Th e anti-Pr3 antibodies were 
passively transferred to wild-type recipient mice and 
found to aggravate subcutaneous panniculitis induced by 
intra dermal injection of TNFα. However, the presence of 
circulating anti-Pr3 antibodies, in contrast to that of anti-
MPO antibodies, did not lead to vasculitic lesions in the 
lungs or kidneys. Along the same line, van der Geld and 
colleagues [41] showed that immunization of mice and 
rats with chimeric human-mouse Pr3 elicited an antibody 
response to mouse Pr3 and rat granulocytes. Again, how-
ever, no signs of vasculitis development were observed in 
these animals. More recently, Primo and colleagues [42] 
attempted to use splenocyte transfer from recombinant 
Pr3-immunized mice to immunodeﬁ cient NOD/SCID 
(nonobese diabetic/severe combined immunodeﬁ ciency 
disease) mice that lack a functioning endogenous 
immune system. Th is splenocyte transfer approach was 
also adopted by Xiao and colleagues [19] in the anti-
MPO model but was abandoned because of the develop-
ment of numerous immune deposits in the vasculitic 
lesions, thereby rendering this model nonrepresentative 
of human vasculitis. Anti-Pr3 antibodies were detectable 
at high levels in recipients of splenocytes from 
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Pr3-immunized mice, all of which developed necrotising 
glomerulo nephritis. Th ese experiments support a possible 
patho genic eﬀ ect of anti-Pr3 antibodies but cannot be 
considered deﬁ nitive, because of the issue of immune 
complex deposition following splenocyte transfer. Th ere-
fore, as convincing animal models are still lacking, our 
knowledge of the pathogenesis of vasculitis induced by 
anti-Pr3 antibodies remains limited.
ANCA SVV: outstanding issues
Clinical and experimental studies in the ﬁ eld of ANCA 
SVV have contributed much to our current knowledge of 
disease pathogenesis, but many questions remain. First, 
despite several attempts and approaches (vide supra), no 
convincing animal model for Pr3-ANCA SVV has yet 
been established. Th is raises the fundamental question of 
whether the pathogenesis of MPO-ANCA vasculitis and 
that of Pr3-ANCA vasculitis are the same. It has been 
recognized that Pr3- and MPO-ANCA SVV patients diﬀ er 
to some extent in their clinical presentation and histo-
pathological characteristics of the vasculitic lesions [43]. 
Compared with patients with MPO-ANCAs, patients 
with Pr3-ANCAs more frequently present with extrarenal 
manifes tations and respiratory tract granu lomas and tend 
to have a higher rate of disease relapses. Moreover, 
systemic injection of high-aﬃ  nity anti-Pr3 antibodies, 
unlike that of anti-MPO antibodies, in mice does not 
cause vascu litis. Th e underlying mechanisms accounting 
for these diﬀ erences are not easily explained but may be 
due to diﬀ erences in the ability of MPO-ANCAs and Pr3-
ANCAs to interact with their target antigens, to activate 
their target cells, or to evoke cellular immune responses 
[43]. Th e discrepancy in pathogenic potential between 
anti-Pr3 and anti-MPO antibodies in animal models may 
also be caused by diﬀ erences in physicochemical proper-
ties of the antigens themselves. For example, the iso-
electric points of murine and human Pr3 (approximately 
7) are far less than that of MPO (greater than 10) [40], and 
this theoretically could result in diﬀ erential inter actions of 
the antigens with negatively charged cell structures. Th us, 
clinical and experimental ﬁ ndings suggest that the patho-
genesis of MPO-ANCA SVV and that of Pr3-ANCA SVV 
may not be the same, although adequate animal models 
need to be established to conﬁ rm this.
Second, why ANCA SVV primarily targets small- to 
medium-sized blood vessels and aﬀ ects susceptible 
organs such as the kidneys and lungs is unclear. However, 
it is likely that the target of these diseases, the endo-
thelium, actively participates in the induction and 
progression of vasculitis. Th rough expression of adhesion 
molecules and generation of cytokines and chemokines, 
activated endothelial cells are important players in 
driving the inﬂ ammatory response. It is also well 
appreciated that endothelial cells from diﬀ erent vascular 
beds are quite heterogeneous in their response to inﬂ am-
matory stimuli, and this is most likely due to organ- and 
function-speciﬁ c adaptations [44]. With this in mind, it 
will be interesting to compare the phenotype of endo-
thelial cells in vascular beds that are aﬀ ected in ANCA 
SVV with those that are resistant. One approach could be 
to analyze gene and protein expression proﬁ les of aﬀ ected 
vascular beds in human tissues and experi mental models 
of ANCA SVV [45]. In the end, such analyses may reveal 
new vascular bed-speciﬁ c targets for treatment. Th ird, 
the reason that ANCAs develop in the ﬁ rst place remains 
unknown, although a number of theories on ANCA 
immunogenesis have been proposed [46],
In a concept analogous to the idiotype network cham-
pioned by Shoenfeld [47], Pendergraft and colleagues [48] 
described the presence of antibodies to a peptide encoded 
by (a portion of) the antisense DNA to the neutrophil 
granule constituent, Pr3. In this ‘theory of autoantigen 
complementarity’, the Pr3-ANCAs are part of an idiotypic 
network, and the authors postulated that some antigens 
expressed on infectious agents (for example, Staphylo-
coccus aureus) may act as the comple men tary antigen. 
Several units around the world are in the process of 
replicating this ﬁ nding of antibodies to complementary 
Pr3 in patients with crescentic glomerulo nephritis.
A second theory invokes molecular mimicry between 
exogenous proteins and the ANCA antigens. Th is theory 
assumes that an initial immune response is evoked against 
pathogen-derived peptides that are highly homolo gous to 
peptide sequences within the ANCA antigens, resulting in 
a cross-reactive immune response against the ANCA self-
antigens. A recent study by Kain and colleagues [49] 
suggests that such a mechanism may operate in ANCA 
SVV. In that study, the authors ob served that circulating 
autoantibodies against lysosomal-associated membrane 
protein 2 (LAMP-2), a heavily glycosylated type 1 
membrane protein involved in cellular adhesion and 
homeostasis, are highly prevalent in patients with active 
focal necrotising crescentic glomerulonephritis, most of 
which were also seropositive for either MPO- or Pr3-
ANCAs. Subsequent experiments revealed potential 
pathogenic eﬀ ects of anti-LAMP-2 antibodies. In vitro, 
anti-LAMP-2 antibodies caused neutrophil and 
endothelial cell activation, and injection of polyclonal 
rabbit anti-LAMP-2 antibodies induced a mild form of 
pauci-immune crescentic glomerulo nephritis in rats. Of 
particular interest is the observation that a major epitope 
recognized by anti-LAMP-2 antibodies has strong 
homology with FimH-1, an adhesin of common Gram-
negative bacteria. Upon immunization with FimH-1, rats 
developed antibodies directed against FimH-1 that cross-
reacted with LAMP-2 and caused crescentic nephritis. 
Overall, these intriguing data suggest that infections with 
Gram-negative bacteria may provoke an autoimmune 
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response to LAMP-2 that in turn induces vasculitis. 
However, since bacterial Gram-negative infections are 
common and ANCA SVV is rare, other factors must also 
be involved in disease induction [50]. Clearly, more 
studies are needed to extend these observations, and 
conﬁ rmation in other patient cohorts is eagerly awaited.
Animal models for ANCA SVV: what is next?
Despite their limitations, the current animal models of 
ANCA vasculitis are likely to be useful for further eluci-
dation of mechanisms and factors involved in disease 
pathogenesis and for identifying targets for treatment. In 
this respect, the murine model is likely to be useful in 
identifying therapeutic targets at the point of acute 
vascular injury, whereas the EAV rat model may be more 
useful in identifying therapies that can be administered 
over a more prolonged period of time to disrupt the 
MPO-speciﬁ c immune response. Th e most pressing 
current need is the development of a reliable model of 
anti-Pr3-associated vasculitis. In addition, we believe 
that the following issues will be important to address 
over the coming 5 to 10 years:
Th e crucial role of neutrophils in ANCA-SVV patho-
genesis is well established but other eﬀ ector cells are 
likely to contribute as well. Besides neutrophils, ANCAs 
can activate monocytes in vitro to produce oxygen 
radicals [51], proinﬂ ammatory cytokines, and chemo-
kines [52]. In addition, macrophages are important 
cellular components of the inﬂ ammatory inﬁ ltrate in 
vasculitic lesions and contribute to glomerular crescent 
formation [53]. Th us, it is of interest to explore the role of 
monocytes/macrophages in disease progression in the 
ANCA vasculitis models. To this end, strategies to 
deplete monocytes/macrophages or modify their func-
tions could be applied in these models.
A rather unexplored area in the SVV models is the role 
of T cells in disease pathogenesis. In the original mouse 
model developed by Xiao and colleagues [19], adoptive 
transfer of splenocytes from mMPO-immunized MPO-
deﬁ cient mice into mice that lack mature B and T cells 
(RAG1−/− mice) caused severe glomerulonephritis. In this 
model, adoptive transfer of pure B cells also induces 
disease manifestations whereas transfer of pure CD4+ 
T  cells does not [54]. Th ese results indicate that, in this 
model, MPO-speciﬁ c CD4+ T cells are not required for 
disease induction but do not rule out a role for these cells in 
the maintenance and propagation of the immune response. 
A study by Ruth and colleagues [55] indeed suggests that 
MPO-ANCA- and MPO-speciﬁ c CD4+ T  cells may work 
together in a unique way. Th ese authors demonstrated that 
immuni zation of C57Bl6 mice with human MPO in 
adjuvant induces a humoral (MPO-ANCA) as well as a 
cellular (MPO-speciﬁ c CD4+ T-cell reactivity) immune 
response. In these mice, an additional challenge with a 
subnephritogenic dose of heterologous anti-GBM anti-
bodies caused glomerular MPO deposition and triggered 
the development of severe crescentic glomerulo nephritis. 
Interestingly, similar experiments performed in B cell-
deﬁ cient mice still resulted in crescentic glomerulo-
nephritis despite the absence of MPO-ANCAs in these 
mice. On the basis of these results, the authors postulated 
that the eﬀ ector phase of MPO-ANCA-associated 
glomerulonephritis is a two-step process requiring (a) 
MPO ANCA-mediated glomerular neutrophil recruit-
ment and release of MPO and (b) CD4+ T-cell eﬀ ector 
responses to induce crescentic glomerulonephritis [55]. 
Th e importance of CD4+ eﬀ ector T cells in anti-MPO 
glomerulonephritis may be conﬁ rmed through studies 
involving transfer of MPO-speciﬁ c T cells from 
immunized Mpo−/− mice into wild-type recipients with or 
without anti-MPO IgG. Using a similar experimental 
setup, Gan and colleagues [56] recently investigated the 
role of T helper 17 (Th 17) cells in autoimmune anti-MPO 
glomerulonephritis. Th 17 cells are a recently identiﬁ ed 
Th  subset characterized by the production of eﬀ ector 
cytokines such as interleukin (IL)-17A, IL-17F, IL-21, and 
IL-22. IL-17A is of particular interest because it has a 
wide range of proinﬂ ammatory properties promoting 
neutrophil and monocyte recruit ment and stimulation of 
release of proinﬂ ammatory cytokines such as TNF and 
IL-1 by macrophages. Interestingly, increased serum 
levels of IL-17 and IL-23 in conjunction with increased 
percentages of circulating Th 17 cells have been detected 
in human ANCA SVV [57]. In their studies, Gan and 
colleagues [56] showed that immunization of C57Bl6 
mice with murine MPO resulted in MPO-speciﬁ c dermal 
delayed-type hyper sensi tivity and systemic IL-17A pro-
duc tion. Upon injection of low-dose anti-GBM anti bodies, 
these mice developed glomerulonephritis. In contrast, 
IL-17A-deﬁ cient mice were almost completely protected 
from disease induction, and this was due in part to 
reduced glomerular neutrophil recruitment. Th ese 
results identify IL-17A as an impor tant eﬀ ector cytokine 
in the patho genesis of MPO-ANCA glomerulonephritis 
and suggest that targeting IL-17A may be a therapeutic 
option. It should be noted, however, that the models 
employed by Ruth and colleagues and Gan and colleagues 
are diﬀ erent from the model originally described by Xiao 
and colleagues [19] because a subnephritogenic dose of 
hetero lo gous anti-GBM antibodies is used to trigger 
disease manifestations. Th us, eﬀ ectively, these are models 
involv ing immune complex deposition in addition to 
anti-MPO autoantibodies.
Besides studies into the role of eﬀ ector cells, further 
elucidation of the pathogenic mechanism of the ANCA 
autoantibodies themselves is of interest. In the mouse 
model, the induced polyclonal anti-MPO antibodies are 
pathogenic, but it is unclear whether disease induction is 
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dependent upon speciﬁ c antibody isotypes or antigen 
epitopes. Th ese issues could be addressed using mono-
clonal antibodies generated from murine MPO-immu-
nized Mpo−/− mice combined with heavy-chain switch 
variants of these monoclonal antibodies [23].
Th e ANCA vasculitis animal models are also likely to 
contribute to the elucidation of genetic risk factors for 
disease development. Until now, genetic studies in 
human ANCA SVV have focused on candidate genes and 
have been hampered by small sample sizes [58]. Although 
large multicenter genome-wide studies in ANCA SVV 
have been initiated and are currently under way, the 
animal models may also oﬀ er opportunities. In the rat 
EAV model, Wistar Kyoto (WKY) rats have been shown 
to be highly susceptible to vasculitis development upon 
immunization with human MPO in complete Freund’s 
adjuvant. In contrast, three other rat strains tested – 
Lewis, Wistar Furth, and Brown Norway – were found to 
be resistant to vasculitis development, although similar 
levels of anti-human MPO antibodies were detected [59]. 
Interestingly, since WKY and Lewis rats share the same 
major histocompatibility complex (MHC) 2 haplotype, 
these observations indicate that susceptibility to vascu-
litis development in this model is dependent on non-
MHC-linked genes [59]. Similarly, preliminary studies in 
the anti-MPO IgG transfer mouse model have shown 
that 129S6 mice are much more susceptible to anti-MPO 
IgG-mediated glomerulonephritis induction than the 
originally used C57Bl6 mice [21]. Since both strains are 
of the H2b MHC haplotype, this again indicates that non-
MHC genes are involved. Collectively, these observations 
in rats and mice now pave the way for more detailed 
genetic studies that will aid in the identiﬁ cation of genetic 
risk factors for human ANCA SVV.
Finally, the rodent models of ANCA SVV may continue 
to be used for the discovery and testing of new targets for 
treatment. Possible target candidates include mediators 
of signalling pathways other than PI3K and P38 MAPK 
that have been shown to be involved in ANCA-mediated 
activation of neutrophils in vitro. Also, new targets may 
be identiﬁ ed by analyzing vascular bed-speciﬁ c gene and 
protein expression patterns or via genome-wide gene 
expression analysis of aﬀ ected tissues. Since the alter na-
tive pathway of complement appears to be pivotal in anti-
MPO-mediated glomerulonephritis in mice, a potential 
therapy could involve inhibition of components critical 
for this pathway, including factor B and properdin. Such 
therapies have been evaluated recently in other inﬂ am-
matory models and could be attractive targets for ANCA 
vasculitis as well [60,61].
Conclusions
Boosted by the development of various animal models 
for MPO-ANCA SVV, our knowledge of the unique 
pathogenic mechanisms involved in ANCA-mediated 
vasculitis has increased tremendously and this will open 
new avenues for therapeutic strategies. At the same time, 
many questions concerning the pathogenesis and 
immuno genesis of ANCA SVV remain. Th e current 
MPO-ANCA models will continue to be helpful in 
providing answers to these questions, although further 
‘ﬁ ne tuning’ of the animal models is necessary. Th e 
development of a convincing in vivo model for Pr3-
ANCA SVV is eagerly awaited.
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